Skip to main content

Together we are beating cancer

Donate now

Cancer News

The latest news, analysis and opinion from Cancer Research UK

Oesophageal cancer

Showing 12 out of 110 results
The capsule sponge shown in pill form and sponge form. Both are black and attached to a white thread.

Our BEST4 Screening trial will give 120,000 people with chronic heartburn a 'pill-on-a-thread' test to look for signs of Barrett's oesophagus, a rare condition that can lead to oesophageal cancer. The results will show whether the UK can use the test for a new oesophageal cancer screening programme. Our BEST4 Screening trial will give 120,000 people with chronic heartburn a 'pill-on-a-thread' test to look for signs of Barrett's oesophagus, a rare condition that can lead to oesophageal cancer. The results will show whether the UK can use the test for a new oesophageal cancer screening programme.

by Tim Gunn | Analysis | 28 November 2024

28 November 2024

A microscope image showing cells affected by Barrett's oesophagus, a precancer that can lead to oesophageal cancer.

For oesophageal cancer awareness month, we’ve rounded up four of our articles on the latest research into oesophageal cancer diagnosis, treatment and prevention.   For oesophageal cancer awareness month, we’ve rounded up four of our articles on the latest research into oesophageal cancer diagnosis, treatment and prevention.  

by Amy Warnock | Analysis | 9 February 2024

9 February 2024

An image of a capsule sponge, a test for Barrett's oesophagus and oesophageal cancer

Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year.  Our BEST4 trial will show if a capsule sponge test can be used to monitor people at high risk of oesophageal cancer. It could give the NHS a quick and simple new screening test for oesophageal cancer and save thousands of lives every year. 

by Tim Gunn | Analysis | 11 January 2024

11 January 2024

Two cancer researchers looking at a cell image on screen

Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs. Each cancer is as unique as the person it affects. By studying patient data, we can target our treatments to people's specific needs.

by Cancer Research UK | In depth | 21 November 2023

21 November 2023

Cancer cells with extrachromosomal DNA (ecDNA)

Cancer Grand Challenges team eDyNAmiC has changed our understanding of how oesophageal cancer starts. In some cases, mutations scientists thought were a late effect of the disease could actually be driving it in the first place. The findings could give us a new way to intercept cancer before it becomes dangerous. Cancer Grand Challenges team eDyNAmiC has changed our understanding of how oesophageal cancer starts. In some cases, mutations scientists thought were a late effect of the disease could actually be driving it in the first place. The findings could give us a new way to intercept cancer before it becomes dangerous.

by Tim Gunn | In depth | 23 October 2023

23 October 2023

The House of Parliament in London

Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types Research from the International Cancer Benchmarking Partnership has found a link between cancer policy consistency over time and survival for six cancer types

by Jacob Smith | Analysis | 1 November 2022

1 November 2022

A packet of Viagra pills

Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect.  Researchers have found a drug that targets the tumour microenvironment that could improve treatment for certain cancers. But it might not be the kind of drug you expect. 

by Jacob Smith | Analysis | 21 June 2022

21 June 2022

Barrett's oesophagus under the microscope

Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now. Barrett’s oesophagus affects around 1 in every 100 to 200 people in the UK, and, for a small number of people, can develop into oesophageal cancer. But the origins of the condition have remained a mystery for decades, until now.

by Harry Jenkins | Analysis | 25 October 2021

25 October 2021

3D representation of oesophageal cancer

The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer. The immunotherapy drug nivolumab (Opdivo) has been made available for some people in England with oesophageal cancer, in what has been described as a ‘step change’ for people with this cancer.

by Harry Jenkins | News | 20 October 2021

20 October 2021

3D rendering of oesophageal cancer

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer. The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for some patients with advanced oesophageal cancer.

by Harry Jenkins | News | 11 August 2021

11 August 2021

Hand holding a Cytosponge pill next to an image of a slide with stained cells

Cancer Research UK-funded researchers have developed a tool to help experts diagnose a condition that can increase the risk of developing oesophageal cancer. Cancer Research UK-funded researchers have developed a tool to help experts diagnose a condition that can increase the risk of developing oesophageal cancer.

by Cancer Research UK | News | 15 April 2021

15 April 2021